Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 2, 2013, Pages 264-270

  Bochenek, MacIej ^a,b   Zalewski, Jaroslaw ^a,b   Sadowski, Jerzy ^a,b   Undas, Anetta ^a,b  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Coronary artery disease; Diabetes mellitus; Fibrin clot; Fibrinolysis; Platelet activation

Indexed keywords

ALTEPLASE; CD40 LIGAND; FIBRINOGEN; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG EFFECT; EX VIVO STUDY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIN; HUMANS; MALE; MIDDLE AGED;

EID: 84877074732     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0821-8     Document Type: Article

References (35)

1. Laakso M (2001) Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 249:225-235
2. Mohan V, Venkatraman JV, Pradeepa R (2010) Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. J Diabetes Sci Technol 4:158-170
3. Kannel W, McGee D (2002) Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038
4. Polakowska M, Piotrowski W (2011) Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study - WOBASZ. Pol Arch Med Wewn 121:156-163
5. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136
6. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT (2000) Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180-2184
7. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A et al (2006) Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26:2567-2573
8. Dunn EJ, Ariëns RA, Grant PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48:1198-1206
9. Undas A (2011) Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 121:110-119
10. Undas A, Ariëns RA (2011) Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:e88-e99
11. Dunn EJ, Philippou H, Ariëns RA, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071-1080
12. Zabczyk M, Butenas S, Palka I, Nessler J, Undas A (2010) Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn 120:334-340
13. Pieters M, Covic N, du Loots T, van der Westhuizen FH, van Zyl DG, Rheeder P et al (2006) The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 96:623-629
14. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P; Novara Atherosclerosis Study Group (NAS) (2011) High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 31:458-463
15. D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, et al (2012) Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2012 Feb 21. [Epub ahead of print]
16. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505
17. Bini A, Fenoglio J, Mesa-Tejada E, Kudryk B, Kaplan K (1989) Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Atherosclerosis 9:1038-1045
18. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H (2006) Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subject. Arterioscler Thromb Vasc Biol 26:1397-1404
19. Undas A, Zalewski J, Krochin M, Siudak Z, Sadowski M, Pregowski J, Dudek D, Janion M, Witkowski A, Zmudka K (2010) Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol 30:276-282
20. Jörneskog G, Hansson LO, Wallen NH, Yngen M, Blombäck M (2003) Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 1:1195-1201
21. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51:189-197
22. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4:1029-1036
23. Wiesel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5:116-124
24. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariëns RA (2010) Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 115:3980-3988
25. Collet JP, Montalescot G, Lesty C, Weisel JW (2002) A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet rich clots. Circ Res 90:428-434
26. Mangiacapra F, Peace AJ, Wijns W, Barbato E (2011) Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. J Thromb Thrombolysis 32:54-58
27. Blann AD (2000) Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 11:623-630
28. Bajzar L, Morser J, Nesheim ME (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 271:16603-16608
29. Boffa MB, Koschinsky ML (2007) Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 40:431-442
30. Schroeder V, Wilmer M, Buehler B, Kohler HP (2006) TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost 96:236-237
31. Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, Aznar J, Estelles A (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122:958-965
32. Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94:811-818
33. Santamaria A, Borrell M, Oliver A, Ortin R, Forner R, Coll I, Mateo J, Souto JC, Fontcuberta J (2004) Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population. Am J Hematol 76:348-352
34. Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M (2003) Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 14:551-556
35. Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y (2002) Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 87:605-660